Clinicopathological response and survival outcomes of HER2-low versus HER2-zero early breast Cancer: A systematic review and Meta-analysis.
Lijuan Liu, Xiaochen Ma, Cun Liu et al.
✦ AI-curated · Sources linked
In 30 seconds
This systematic review and meta-analysis evaluated the clinicopathological response and survival outcomes of HER2-low versus HER2-zero early breast cancer in 115,182 patients. The study found that HER2-low patients had significantly lower pathological complete response (pCR) rates (OR = 0.58) but better disease-free survival (DFS) (multivariate HR = 0.75) and overall survival (OS) (HR = 0.80), particularly in hormone receptor-negative tumors.
Key findings
- HER2-low patients had significantly lower pCR rates compared to HER2-zero (OR = 0.58).
- Disease-free survival favored HER2-low patients with a multivariate HR of 0.75.
- Overall survival was better for HER2-low patients, with an HR of 0.80, especially in HR-negative tumors.
Why it matters
Understanding the differences in outcomes between HER2-low and HER2-zero breast cancer can inform treatment strategies and prognostic assessments, highlighting the importance of HER2-low as a distinct subgroup within HER2-negative disease.